Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Suzhou Ribo Life Science
company
About
Suzhou Ribo Life Science develops nucleic acid drugs and related products based on the RNA interference technology.
- 51 - 100
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $28.78M
- Industries
- Biotechnology,Genetics,Medical
- Founded date
- Jan 1, 2007
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Suzhou Ribo Life Science is a developer of RNA interference ( RNAi ) technology designed to treat liver diseases. The company's RNA interference ( RNAi ) technology is used to develop nucleic acid therapeutic drugs and related products, enabling healthcare providers to deliver more effective pharmaceuticals to patients.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$28.78M ¥270M
Suzhou Ribo Life Science has raised a total of
$28.78M ¥270M
in funding over 2 rounds. Their latest funding was raised on
Dec 5, 2019 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 5, 2019 | Series C | $28.78M | 2 | — | — | Detail |
| Mar 20, 2017 | Series B | ¥270M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
Suzhou Ribo Life Science is funded by 3 investors.
Daxie Yungong Investment
and Hanyang Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
|
|
— | Series C |
Lotus Lake Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
